Golcadomide — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

7 Recruiting

2 Completed trials

6 Sponsors

18 Countries

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II: 4 Phase I/II: 3

Oversight events:

1 temporary halt 1 urgent safety measure 1 unexpected event across 1 trial

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 3 Mantle cell lymphoma 1 B-cell lymphoma refractory 1 Follicular lymphoma 1 Follicular lymphoma stage IV 1 Epstein-Barr virus associated lymphoma 1 Diffuse large B-cell lymphoma refractory 1 Follicular lymphoma stage III 1 Marginal zone lymphoma 1 Follicular lymphoma stage II 1

Sponsors using this IMP

Celgene Corp. 4 AbbVie Deutschland GmbH & Co. KG 1 Fondazione Italiana Linfomi Ets 1 Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting 1 Lymphoma Academic Research Organisation 1 LYSARC 1

All trials

9 total

A phase 2 study of the effectiveness of golcadomide (CC-99282) for patients with large B-cell lymphoma in the brain Recruiting

2024-517051-12-00 Phase II 2 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants… Recruiting

2024-519152-82-00 Phase III 8 countries Celgene Corp.
PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS Recruiting

2024-514954-63-00 Phase I/II 1 country LYSARC
Clinical trial with a combination of Rituximab and Golcadomide as first line therapy for older frail patients with Diffuse Large B-cells non… Recruiting

2023-506206-38-00 Phase II 1 country Fondazione Italiana Linfomi Ets
CARMOD - Golcadomide (BMS-986369) post-CAR T-cell in R/R Aggressive large B-cell lymphoma patients with high risk of relapse Recruiting

2023-506705-20-00 Phase II 1 country Lymphoma Academic Research Organisation
This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Recruiting

2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) Recruiting

2024-515690-10-00 Phase I/II 4 countries Celgene Corp.
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended

2024-511304-16-00 Phase II 5 countries Celgene Corp.
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 Phase III 17 countries Celgene Corp.

Showing 1–9 of 9 trials

← All drugs A–Z